ARRAY BIOPHARMA INC's ticker is ARRY and the CUSIP is 04269X105. A total of 172 filers reported holding ARRAY BIOPHARMA INC in Q3 2016. The put-call ratio across all filers is 1.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $45,781,000 | +17.0% | 992,510 | -38.2% | 0.57% | +14.0% |
| Q1 2019 | $39,143,000 | +63.6% | 1,605,480 | -4.4% | 0.50% | +36.1% |
| Q4 2018 | $23,921,000 | +16.5% | 1,678,710 | +24.2% | 0.37% | +34.8% |
| Q3 2018 | $20,538,000 | +63.2% | 1,351,188 | +80.2% | 0.27% | +37.2% |
| Q2 2018 | $12,584,000 | +34.1% | 749,888 | +30.4% | 0.20% | +24.4% |
| Q1 2018 | $9,384,000 | +35.8% | 575,000 | +6.5% | 0.16% | +33.3% |
| Q4 2017 | $6,912,000 | -24.5% | 540,000 | -27.4% | 0.12% | -25.0% |
| Q3 2017 | $9,151,000 | +135.1% | 744,000 | +60.0% | 0.16% | +119.2% |
| Q2 2017 | $3,892,000 | -4.3% | 465,000 | +2.2% | 0.07% | -7.6% |
| Q1 2017 | $4,068,000 | -38.7% | 455,000 | -39.7% | 0.08% | -48.0% |
| Q4 2016 | $6,636,000 | +21.4% | 755,000 | -6.8% | 0.15% | +15.2% |
| Q3 2016 | $5,468,000 | +80.9% | 810,000 | -4.6% | 0.13% | +67.1% |
| Q2 2016 | $3,023,000 | +56.3% | 849,000 | +28.8% | 0.08% | +64.6% |
| Q1 2016 | $1,934,000 | – | 659,000 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Redmile Group, LLC | 15,978,580 | $268,121,000 | 9.11% |
| BVF INC/IL | 4,672,195 | $78,399,000 | 7.65% |
| First Light Asset Management, LLC | 2,391,575 | $40,131,000 | 6.25% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 694,500 | $11,647,000 | 4.47% |
| Copernicus Capital Management, LLC | 286,797 | $4,812,000 | 3.49% |
| PACIFIC VIEW ASSET MANAGEMENT, LLC | 225,511 | $3,784,000 | 3.00% |
| SECTORAL ASSET MANAGEMENT INC | 1,566,477 | $26,285,000 | 2.94% |
| X-Square Capital, LLC | 173,802 | $2,917,000 | 2.18% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,618,654 | $43,941,000 | 1.48% |
| Birchview Capital, LP | 128,000 | $2,148,000 | 1.46% |